Generate Investment Management Ltd Acquires 259,265 Shares of Boston Scientific Corporation $BSX

Generate Investment Management Ltd raised its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 190.9% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 395,081 shares of the medical equipment provider’s stock after purchasing an additional 259,265 shares during the period. Boston Scientific makes up approximately 2.0% of Generate Investment Management Ltd’s portfolio, making the stock its 14th biggest holding. Generate Investment Management Ltd’s holdings in Boston Scientific were worth $38,572,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of BSX. Forefront Wealth Partners LLC purchased a new position in shares of Boston Scientific during the third quarter valued at approximately $206,000. Sivia Capital Partners LLC raised its position in Boston Scientific by 9.9% in the 3rd quarter. Sivia Capital Partners LLC now owns 4,780 shares of the medical equipment provider’s stock valued at $467,000 after buying an additional 432 shares during the last quarter. Weaver Capital Management LLC bought a new position in Boston Scientific during the 3rd quarter valued at $263,000. Diversified Trust Co lifted its stake in Boston Scientific by 17.4% during the 3rd quarter. Diversified Trust Co now owns 6,040 shares of the medical equipment provider’s stock valued at $590,000 after acquiring an additional 896 shares in the last quarter. Finally, Simplify Asset Management Inc. boosted its holdings in Boston Scientific by 13.9% during the 3rd quarter. Simplify Asset Management Inc. now owns 8,087 shares of the medical equipment provider’s stock worth $790,000 after acquiring an additional 984 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Up 0.2%

Boston Scientific stock opened at $95.98 on Wednesday. The firm has a 50 day moving average price of $98.36 and a 200-day moving average price of $101.05. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The company has a market capitalization of $142.28 billion, a P/E ratio of 51.32, a P/E/G ratio of 1.93 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter in the prior year, the business earned $0.63 earnings per share. Boston Scientific’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,739,678.74. The trade was a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 93,095 shares of company stock valued at $9,305,450 in the last 90 days. Insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on BSX. Robert W. Baird increased their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Erste Group Bank lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, December 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $121.00 target price on shares of Boston Scientific in a report on Friday, October 17th. Finally, Evercore ISI reaffirmed an “outperform” rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Boston Scientific has an average rating of “Buy” and an average price target of $124.85.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.